Nucala Archives -

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment

FDA says no to AZ’s Fasenra for nasal polyp indication

https://pharmaphorum.com/news/fda-says-no-to-azs-fasenra-for-nasal-polyp-indication/

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

https://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/

GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation

GSK eyes nasal polyps use for Nucala after trial success

https://pharmaphorum.com/news/gsk-eyes-nasal-polyps-use-for-nucala-after-trial-success/

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs

Shingrix and Trelegy shield GSK from Advair fallout

https://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/

With competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes

EU clears GSK’s asthma drug Nucala in patient-friendly format

https://pharmaphorum.com/news/eu-clears-gsks-asthma-drug-nucala-in-patient-friendly-format/

Nucala